Amarin Corporation PLC
AMRN
View Detailed Chart
15.710USD
+0.040+0.26%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
326.74MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.26%
5 Days
-3.56%
1 Month
-18.47%
6 Months
+54.32%
Year to Date
+61.96%
1 Year
+36.49%
View Detailed Chart
TradingKey Stock Score of Amarin Corporation PLC
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Sell. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amarin Corporation PLC's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Sell
Current Rating
11.333
Target Price
-27.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amarin Corporation PLC Highlights
StrengthsRisks
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Overvalued
The company’s latest PE is -3.76, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.72M shares, decreasing 22.01% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 0.00 shares of this stock.
Amarin Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Amarin Corporation PLC Info
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Ticker SymbolAMRN
CompanyAmarin Corporation PLC
CEOMr. Aaron D. Berg
Websitehttps://amarincorp.com/
Related Instruments
-1.39%
-0.21%
+0.05%
+0.97%
-0.17%
-0.77%
+0.58%
+1.46%
-1.78%
-3.70%
-1.69%
+0.34%
-1.63%
+0.13%
-1.00%
+0.53%
0.00%
+1.65%
+0.50%
+0.57%Popular Symbols
